# JOJO share price today (JOJO Ltd, BSE: 531910)

> JOJO share price today: ₹109.90 at the BSE close on 3 November 2026, up 138.7% in a year. JOJO (BSE: 531910) is worth ₹1,510 crore, trades at a P/E of 214.9 and has closed between ₹47.48 and ₹120.00 over the past 52 weeks. > JOJO Ltd is reporting record margins. 531910 · Pharma - Others · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/jojo-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹109.90 (+138.7% in a year)
- P/E: 214.9× (higher than 55% of the last 9.4 years)
- Revenue (Jun 2026): ₹4.5 Cr (+152.5% on a year ago)
- Profit (Jun 2026): ₹0.9 Cr
- Operating margin: 44.7% (+53.1 points on a year ago)
- ROCE: 17%, FY26

The main question: promoters moved −3.3 percentage points over 8 quarters while the business went the other way. ## What is the JOJO share price today? JOJO Ltd's share price was ₹109.90 at the close on 3 November 2026. It has been rising for 13 weeks. That is 40.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹47 and ₹120, and at that close it sat 86% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 16 weeks in a row. Over the last 11 years the share price moved +11,468% while the NIFTY 500 moved +249%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at JOJO this quarter? 6 points in one quarter and revenue up on a year earlier for 5 quarters in a row. 1. Operating margin up 53.1 points on a year earlier 44.7% in the June 2026 quarter, from -8.4%. 2. Promoters cut their stake by 4.6 points in one quarter From 67.8% to 63.2% in the October 2026 quarter. 3. Revenue up on a year earlier for 5 quarters in a row In the June 2026 quarter revenue was ₹5 crore, +152.5% on a year earlier. ## What are JOJO's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), JOJO reported revenue of ₹4.52 crore, up 152.5% from ₹1.79 crore a year earlier, and a profit of ₹0.90 crore, against a loss of ₹0.51 crore a year earlier. ### JOJO results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹4.52 crore | ₹1.79 crore | +152.5% |
| Profit | ₹0.90 crore | loss of ₹0.51 crore | n/a |
| Earnings per share | ₹0.07 | ₹−0.05 | n/a |
| Operating margin | 44.7% | −8.4% | +53.1 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the JOJO share price history? JOJO closed at ₹109.90 on 3 November 2026, up 138.7% from ₹46.05 a year earlier (31 October 2025) and up 17,344.4% over five years. Its highest weekly close since March 2016 was ₹120.00 on 16 October 2026. ### JOJO share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹116.50 | −5.7% |
| 1 month ago · 1 Oct 2026 | ₹112.60 | −2.4% |
| 6 months ago · 30 Apr 2026 | ₹58.23 | +88.7% |
| 1 year ago · 31 Oct 2025 | ₹46.05 | +138.7% |
| 3 years ago · 3 Nov 2023 | ₹13.84 | +694.1% |
| 5 years ago · 11 Oct 2021 | ₹0.63 | +17,344.4% |
| 10 years ago · 11 Nov 2016 | ₹0.92 | +11,845.7% |
| Earliest weekly close in our records · 3 Mar 2016 | ₹0.95 | +11,468.4% |
| Highest weekly close since March 2016, also the 52-week high · 16 Oct 2026 | ₹120.00 | −8.4% |
| Lowest weekly close since March 2016 · 22 Nov 2017 | ₹0.27 | +40,603.7% |
| 52-week low (weekly close) · 2 Apr 2026 | ₹47.48 | +131.5% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (316 weekly closes from 3 March 2016 to 3 November 2026.)

## What is the latest news on JOJO? 3 Nov 2026: JOJO closed at ₹109.90, down 5.7% on the week and down 2.4% on the month. Results for April to June 2026: Revenue up 152.5% on a year earlier. ## What dividend does JOJO pay? No. JOJO Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate (as of 3 November 2026). ## Which stock lists is JOJO on? JOJO is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market cap cr: 1509.337516808606](https://www.sectoralpha.in/momentum-stocks-india)
- [Pharma stocks Market value (₹ crore): 1509.337516808606](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is JOJO profitable? JOJO Ltd earned ₹0.9 Cr of net profit in the Jun 2026 quarter. Full-year FY26 profit was ₹5.6 Cr. Over 10 years profit has grown 88.4% a year on average. That is 19.9% of the quarter's revenue. The same quarter a year earlier lost ₹0.5 Cr. 4 of the last 12 reported quarters were loss-making. ## How much revenue does JOJO make, and is it growing? JOJO Ltd reported ₹4.5 Cr of revenue in the Jun 2026 quarter, +152.5% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 10 years it has grown 71.4% a year on average. The last full year, FY26, came in at ₹24.0 Cr. The last four reported quarters add to ₹26.7 Cr. FY26 revenue was ₹24.0 Cr, +448.2% on the year before. Recent pace: the last four quarters grew +330.2% on average, against 71.4% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +335.5%, against +135.3% a year over the last 8 quarters (accelerating). ## How much of every ₹100 of sales does JOJO keep? JOJO Ltd's operating margin was 44.7% in the Jun 2026 quarter, 53.1 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between −400.0% and 42.7%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +53.1 percentage points on the year while gross margin changed +0.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is JOJO's profit turning into cash? Over the last 3 years, 123% of JOJO Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹10.5 Cr of operating cash against ₹5.6 Cr of profit. After ₹14.0 Cr of spending on assets, free cash was −₹3.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does JOJO's cash go? JOJO Ltd's customer, stock and supplier day counts come out in the thousands of days on sales this small (₹24.0 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹36.0 Cr on assets over the last 3 years. Averaged over those years that is 50.0% of FY26 revenue a year. Spending on assets: ₹36.0 Cr over the last 3 years, against ₹4.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹9.8 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is JOJO's P/E ratio, and how does it compare with its own history? JOJO Ltd's P/E is 214.9×, in the middle of its own history: higher than 55% of past readings. Its usual P/E (the middle reading) is 156.3×, over 9.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹0.67. Where the price move came from: over 5 years the price moved +180.8% a year; about +119.5% a year came from earnings growth and about +61.3 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the JOJO business getting better or worse? JOJO Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does JOJO earn on its capital? JOJO Ltd earned a ROCE of 17% in FY26. That is up from a low of −4% in FY15. Its return on capital used (ROIC) is left out: on sales this small it reads 14%, a number that says nothing useful about the business. It comes from a 23.4% net margin and 0.30× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 23.4% net margin × 0.30× asset turnover × 1.47× leverage (assets divided by equity) ≈ 10.3% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. ## Does JOJO have too much debt? JOJO Ltd had ₹3.2 Cr of borrowings against ₹54.2 Cr of equity in FY26, so its debt is 0.06× its equity. Over 5 years borrowings went from ₹0.1 Cr to ₹3.2 Cr. Over the last 3 of those years it spent ₹36.0 Cr on assets. Part of the spending on assets is being paid for with borrowed money. ## What is the JOJO shareholding pattern? Promoters cut their stake in JOJO Ltd by 3.3 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 63.2% of the company. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Why the owners changed: promoters drove it (−3.3 points). They reduced their stake. ## How far is JOJO from balance-sheet trouble? For JOJO Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does JOJO rank in its industry? 61.6 out of 100, rank 8 of 10 in Pharma - Others, with 48% of the evidence available. It is provisional, so it is ranked below companies with full evidence. JOJO Ltd scores 61.6 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 8. Some evidence is missing, so the score is pulled toward the middle on purpose. The three scored parts add up to the total exactly: 31.1 + 19.4 + 11.1 = 61.6 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is JOJO compared with? JOJO ranks 8 of 10 Pharma - Others companies on the 4-Factor Sector Score, with 61.6 out of 100. 1. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) SYNCOMF · breaking out · Most evidence points up · 89% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 0.4% · Profit 48.3% · Operating margin change 7 points · 88% evidence Capital efficiency 17.2/25 · ROCE 24.7% · Operating margin 21% · 100% evidence Valuation 15.1/20 · P/E 21.2× · PEG 0.79 · 65% evidence Relative strength 17.8/20 · Lead over its industry -0.2% · Lead over NIFTY 500 32.3% · 1 year 16.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.4 + 17.2 + 15.1 + 17.8 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Shukra Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd) SHUKRAPHAR · breaking out · Too little evidence to rank firmly · 56% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/35 · Revenue 100% · Profit 100% · Operating margin change 66 points · 83% evidence Capital efficiency 19.4/25 · ROCE 37% · Operating margin 90% · 76% evidence Valuation 9.3/20 · P/E 91.9× · PEG n/a · 15% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 83.7% · 1 year 82.8% · 25% evidence · 6 of 6 weeks ahead Exact sum: 28.5 + 19.4 + 9.3 + 12.5 = 69.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 3. [Sun Pharma Advanced Research Company Ltd](https://www.sectoralpha.in/stocks/sun-pharma-advanced-research-company-ltd) SPARC · quiet · Evidence leans up · 78% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 100% · Profit 100% · Operating margin change 455 points · 65% evidence Capital efficiency 16.0/25 · ROCE 164% · Operating margin -85% · 100% evidence Valuation 15.0/20 · P/E 3.6× · PEG n/a · 50% evidence Relative strength 4.3/20 · Lead over its industry -17.4% · Lead over NIFTY 500 9.3% · 1 year 30.9% · 100% evidence · 1 of 12 weeks ahead Exact sum: 25.8 + 16 + 15 + 4.3 = 61.1 · What this means: Earnings are strong; relative strength in its sector is -17.4% and the one-year return is 30.9%. 4. [Remus Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd) REMUS · breaking out · Too little evidence to rank firmly · 54% evidence 54.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 57.3% · Profit 80% · Operating margin change -4 points · 27% evidence Capital efficiency 13.3/25 · ROCE 11.5% · Operating margin 32% · 57% evidence Valuation 11.2/20 · P/E 41.2× · PEG n/a · 50% evidence Relative strength 12.8/20 · Lead over its industry -12.6% · Lead over NIFTY 500 16.6% · 1 year 17.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.5 + 13.3 + 11.2 + 12.8 = 54.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) TTKHLTCARE · quiet · Evidence leans up · 85% evidence 50.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 11.3% · Profit 100% · Operating margin change -1 points · 100% evidence Capital efficiency 6.8/25 · ROCE 8% · Operating margin 1.6% · 100% evidence Valuation 15.7/20 · P/E 17.6× · PEG 1.38 · 100% evidence Relative strength 8.4/20 · Lead over its industry n/a · Lead over NIFTY 500 -3% · 1 year -23.1% · 25% evidence · 10 of 12 weeks ahead Exact sum: 19.8 + 6.8 + 15.7 + 8.4 = 50.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Unichem Laboratories Ltd](https://www.sectoralpha.in/stocks/unichem-laboratories-ltd) UNICHEMLAB · losing its lead · Evidence leans down · 64% evidence 38.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.4/35 · Revenue 7.2% · Profit 100% · Operating margin change 6.7 points · 62% evidence Capital efficiency 6.6/25 · ROCE 4.1% · Operating margin 11% · 76% evidence Valuation 10.0/20 · P/E 27.9× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry -13.3% · Lead over NIFTY 500 15.4% · 1 year 2.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.4 + 6.6 + 10 + 8.3 = 38.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) PANACEABIO · basing · Most evidence points down · 76% evidence 20.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.2/35 · Revenue 10.3% · Profit -80% · Operating margin change 3.5 points · 88% evidence Capital efficiency 1.2/25 · ROCE -2.4% · Operating margin 2.8% · 100% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 1.0/20 · Lead over its industry -38.3% · Lead over NIFTY 500 -16.4% · 1 year -28.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 8.2 + 1.2 + 10 + 1 = 20.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. JOJO Ltd this page leader · Too little evidence to rank firmly · 48% evidence 61.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.1/43.75 · Revenue 100% · Profit 100% · Operating margin change 53.1 points · 62% evidence Capital efficiency 19.4/31.25 · ROCE 16.8% · Operating margin 44.7% · 95% evidence Valuation 11.1/25 · P/E 219× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.1 + 19.4 + 11.1 = 61.6 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Jenburkt Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jenburkt-pharmaceuticals-ltd) Too little evidence to rank firmly · 47% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/43.75 · Revenue 11.8% · Profit 6.1% · Operating margin change 6 points · 53% evidence Capital efficiency 21.8/31.25 · ROCE 27.2% · Operating margin 32% · 71% evidence Valuation 14.3/25 · P/E 13.2× · PEG n/a · 50% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.6 + 21.8 + 14.3 = 56.7 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [Madhuveer Com 18 Network Ltd](https://www.sectoralpha.in/stocks/madhuveer-com-18-network-ltd) MADHUVEER · Too little evidence to rank firmly · 33% evidence 42.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.5/43.75 · Revenue 68.7% · Profit 12.8% · Operating margin change 18.4 points · 45% evidence Capital efficiency 11.7/31.25 · ROCE -1.1% · Operating margin 69.7% · 57% evidence Valuation 10.6/25 · P/E 660× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.5 + 11.7 + 10.6 = 42.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Others](https://www.sectoralpha.in/sectors/pharma-others), all 10 compared on one page. ## Which companies are close to JOJO in size? JOJO is the 6th largest of 10 Pharma - Others companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Shukra Pharmaceuticals, Panacea Biotec and Syncom Formulations (India). Just below it: TTK Healthcare, Remus Pharmaceuticals and Madhuveer Com 18 Network. ### Pharma - Others companies close in size

1. [Shukra Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd) ₹3,313 crore
2. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) ₹1,919 crore
3. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) ₹1,809 crore
4. JOJO Ltd ₹1,539 crore
5. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) ₹1,279 crore
6. [Remus Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd) ₹994 crore
7. [Madhuveer Com 18 Network Ltd](https://www.sectoralpha.in/stocks/madhuveer-com-18-network-ltd) ₹581 crore

[All 10 Pharma - Others companies, largest first](https://www.sectoralpha.in/sectors/pharma-others#all-companies)

### Companies close in size in other industries

1. [Dynamic Cables Ltd](https://www.sectoralpha.in/stocks/dynamic-cables-ltd) ₹1,542 crore · Cables - Power
2. [Quadrant Future Tek Ltd](https://www.sectoralpha.in/stocks/quadrant-future-tek-ltd) ₹1,541 crore · Railways - Kavach/Springs
3. JOJO Ltd ₹1,539 crore
4. [Panorama Studios International Ltd](https://www.sectoralpha.in/stocks/panorama-studios-international-ltd) ₹1,539 crore · Entertainment & Media
5. [Vidhi Specialty Food Ingredients Ltd](https://www.sectoralpha.in/stocks/vidhi-specialty-food-ingredients-ltd) ₹1,538 crore · Dyes & Pigments

## What else do people ask about JOJO? ### What is JOJO's share price today? JOJO Ltd's share price is ₹109.90, +138.7% over the past year. The whole company is worth ₹1,510 Cr on the market. In the last 52 weeks it traded between ₹47 to ₹120; today it is 86% of the way up from the low, 40.1% above its 200-day average (as of 3 November 2026). ### What were JOJO's latest quarterly results? JOJO Ltd reported revenue of ₹4.5 Cr and net profit of ₹0.9 Cr for the Jun 2026 quarter. Earnings per share were ₹0.07. The operating margin was 44.7%, 53.1 percentage points higher than a year earlier (as of 3 November 2026). ### What is JOJO's market cap? JOJO Ltd's market capitalisation is ₹1,510 Cr at a share price of ₹109.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is JOJO performing? JOJO Ltd's share price has been rising for 13 weeks. Over the past 13 weeks it has done better than the NIFTY 500, for 16 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will JOJO's share price go up? This page does not forecast JOJO Ltd's share price. What it shows instead: the share price is ₹109.90, and it has been rising for 13 weeks. Its P/E of 214.9× is higher than 55% of its own last 9 years (as of 3 November 2026). ### Who owns JOJO? Promoters own 63.2% of JOJO Ltd, foreign institutions , domestic institutions, and the public 36.8% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 3.3 percentage points over 8 quarters (as of 3 November 2026). ### Where is JOJO in its business cycle? JOJO Ltd's FY26 operating margin was 42.7%, against a 13-year range of −400.0% to 42.7%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 44.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the JOJO story? The main question: promoters moved −3.3 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is JOJO a stock worth studying right now? What the numbers show: JOJO Ltd is reporting record margins. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.